Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Decrease in Short Interest
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Decrease in Short Interest
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) saw a significant decrease in short interest in June. As of June 15th, there was short interest totalling 43,000 shares, a decrease of 21.7% from the May 31st total of 54,900 shares. Based on an average trading volume of 15,000 shares, the short-interest ratio is presently 2.9 days.
生物綠洲科技公司(BiOASIS Technologies Inc.)6月份的空頭股數銷量大幅下降。截至6月15日，空頭股數共有43,000股，比5月31日的54,900股減少了21.7%。以15,000股的平均成交量計算，目前短息比率為2.9天。
Shares of BIOAF stock opened at $0.13 on Tuesday. The firm has a fifty day moving average of $0.17 and a 200-day moving average of $0.19. Bioasis Technologies has a 12-month low of $0.13 and a 12-month high of $0.34. The company has a market capitalization of $9.28 million, a price-to-earnings ratio of -2.55 and a beta of 0.32.
週二，BIOAF的股票開盤報0.13美元。該公司的50日移動均線切入位為0.17美元，200日移動均線切入位為0.19美元。BiOasis Technologies的12個月低點為0.13美元，12個月高位為0.34美元。該公司市值為928萬美元，市盈率為-2.55倍，貝塔係數為0.32。
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last issued its quarterly earnings data on Tuesday, June 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. As a group, sell-side analysts predict that Bioasis Technologies will post -0.03 earnings per share for the current fiscal year.
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)最近一次發佈季度收益數據是在6月14日(星期二)。該公司公佈了該季度每股收益(EPS)(0.01美元)。賣方分析師預測，作為一個整體，BiOasis Technologies本財年的每股收益將達到0.03美元。
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技術公司是一家處於發展階段的生物製藥公司，致力於神經疾病和障礙的診斷和治療產品的研究和開發。它正在開發xB3，這是一種跨越血腦屏障(BBB)提供治療藥物的平臺技術；以及治療中樞神經系統疾病，包括腦癌以及代謝和神經退行性疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- MarketBeat Podcast: Is The Market Near a Bottom, Does it Matter?
- Institutional Support For KB Home Remains High
- Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- 免費獲取StockNews.com關於BiOASIS技術的研究報告(BIOAF)
- MarketBeat Podcast：市場接近底部了嗎？這重要嗎？
- 對KB Home的機構支持仍然很高
- 使用MarketBeat市場數據工具在熊市中尋找強勁的股票
- 施尼策鋼鐵在強勁國內需求的支持下實現了強勁的季度業績
- MarketBeat：回顧中的一週6/27-7/1
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BiOasis Technologies及相關公司的評級的每日摘要。